Tilray (NASDAQ:TLRY) Posts Quarterly Earnings Results, Misses Expectations By $0.07 EPS

Tilray (NASDAQ:TLRY) issued its earnings results on Friday. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.07), Zacks reports. The firm had revenue of $210.90 million during the quarter, compared to analyst estimates of $216.34 million. Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. The business’s revenue was up 8.7% on a year-over-year basis. Tilray updated its FY 2025 guidance to EPS.

Tilray Stock Performance

Tilray stock opened at $1.23 on Friday. The company has a current ratio of 2.47, a quick ratio of 1.57 and a debt-to-equity ratio of 0.08. Tilray has a 1 year low of $1.14 and a 1 year high of $2.97. The company has a market cap of $1.11 billion, a PE ratio of -4.56 and a beta of 2.08. The company’s 50-day moving average is $1.36 and its two-hundred day moving average is $1.62.

Analyst Ratings Changes

Separately, Roth Mkm reduced their price target on shares of Tilray from $2.00 to $1.75 and set a “neutral” rating on the stock in a research report on Friday, October 11th.

Insider Buying and Selling at Tilray

In related news, CFO Carl A. Merton purchased 26,000 shares of the stock in a transaction dated Friday, November 15th. The stock was bought at an average cost of $1.36 per share, with a total value of $35,360.00. Following the purchase, the chief financial officer now directly owns 26,000 shares in the company, valued at $35,360. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 0.87% of the company’s stock.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.